Cite
Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies.
MLA
Zhen, David B., et al. “Irinotecan-Associated Dysarthria: A Single Institution Case Series with Management Implications in Patients with Gastrointestinal Malignancies.” Journal of Oncology Pharmacy Practice, vol. 25, no. 4, June 2019, pp. 980–86. EBSCOhost, https://doi.org/10.1177/1078155218763044.
APA
Zhen, D. B., McDevitt, R. L., Zalupski, M. M., & Sahai, V. (2019). Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies. Journal of Oncology Pharmacy Practice, 25(4), 980–986. https://doi.org/10.1177/1078155218763044
Chicago
Zhen, David B, Rachel L McDevitt, Mark M Zalupski, and Vaibhav Sahai. 2019. “Irinotecan-Associated Dysarthria: A Single Institution Case Series with Management Implications in Patients with Gastrointestinal Malignancies.” Journal of Oncology Pharmacy Practice 25 (4): 980–86. doi:10.1177/1078155218763044.